Clinical trial
A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)
NCT07561294 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Observer-blind, Dose-finding, Placebo-controlled Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982, an mRNA Vaccine to Prevent Lyme Disease in Healthy Adult Participants (18 to 70 Years of Age)
- Lead sponsor
- ModernaTX, Inc.
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 29, 2026
- Completion date
- November 9, 2028
- Enrollment
- 366 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.